[ad_1]
BRASÍLIA – Representatives of the Ministry of Health said on Friday that there will be no vaccine for the entire Brazilian population in 2021. In addition to the insufficient quantity, there are groups that are not participating in the tests, such as children and pregnant women, and that, therefore They should not be vaccinated initially, explained Francieli Fontana, coordinator of the portfolio’s National Immunization Program, when asked if the ministry has already ruled out offering vaccine to everyone next year:
– We set targets (with priority groups) for vaccination, because we do not have a vaccine to vaccinate the entire Brazilian population. Furthermore, the studies do not foresee working with all age groups initially, so we could not even vaccinate the entire Brazilian population.
COVID-19:In one week, the queue of UCI beds grows 140% in the SUS network in Rio; the state moving average rose for the eleventh day
According to the portfolio, the target audience for the vaccine will continue to be defined, when the immunizer is closer to being available, due to the need to evaluate the characteristics of the substance, including indications. But, according to Elcio Franco, executive secretary of the ministry, the groups at risk of suffering a serious illness, age group, comorbidities and even “ethnic aspects” will be taken into account.
Franco affirmed that the population will be safe, even with unvaccinated groups, comparing the vaccination schedule for Covid-19 with that for influenza (influenza), which occurs every year with the goal of reaching 80 million Brazilians:
– The fact that certain groups of the population are not immunized does not mean that they are not safe, because other groups that live with them are immunized and therefore will not have the possibility of being contaminated with the disease. That is why we do not vaccinate the entire population, for example, against influenza.
Covid Progress: Gateway of patients with Covid-19 in the public network, the UPAs in RJ are in chaos: ‘Are we going to see people die at home?
The secretary stated that, even from the international point of view, there is no expectation of having a vaccine for everyone, citing that the Covax Facility, a consortium that brings together several countries for the production of immunizers against Covid-19, aims ” access to 2 billion doses to vaccinate the world “.
– And then we see that it is a very ambitious goal, because we do not imagine that there will be a vaccine to vaccinate all the citizens of planet Earth – said the secretary.
In Brazil, four vaccines are being tested. This Friday, the Janssen-Cilag laboratory, responsible for one of the studies in the country, sent a package of efficacy and safety data verified in the investigation for evaluation by the National Health Surveillance Agency (Anvisa).
The objective, with the partial sending of the data, as it occurs, is to expedite a future application for registration with the regulatory agency. The method, called continuous presentation, was created for the context of the pandemic, which requires the urgency of public agencies. Traditionally, all information is only sent at the end of surveys.
Understand:Is Brazil experiencing a second wave of Covid-19 or a rebound from the first?
Janssen-Cilag is the fourth laboratory to send data to Anvisa. As a result, all pharmaceutical companies with ongoing vaccine research in Brazil have already started submitting information to the agency. None have yet applied for the vaccine registration.
The federal government supports, even with allocated resources, the vaccine developed by AstraZeneca in partnership with the University of Oxford, which may be manufactured by Fiocruz in the country, if approved by Anvisa. Brazil also participates in the Covax Facility consortium.
Discover: Brazil approaches the 172,000 mark for coronavirus deaths
The estimated portfolio, published in October, had around 140 million doses available to the Brazilian population in the first half of 2021 through the two initiatives (AstraZeneca and Covax). And a second phase, with production of up to 165 million doses still next year, according to information from the Ministry of Health portal.
It is not known how many doses will be required for each person of the vaccine to be recorded. Additionally, AstraZeneca’s investigation was hampered by flaws that arose around applying the wrong dosage and a lack of transparency about what happened.
